Establishment of a treatment for advanced hepatocellular carcinoma using a tri-functional specific antibody

对于晚期肝细胞癌的所有治疗方法尚未建立，我们一直在做这项研究的目的是开发治疗性抗体作为理想的治疗药物。我们已经证明干扰素（IFN）-α/β诱导几种人肝癌细胞中成纤维细胞生长因子受体-1（FGFR-1）表达的上调。基于这一结果，我们已经创建了几种抗FGFR-1单克隆抗体（MoAb）。我们揭示了抗FGFR-1单克隆抗体和干扰素-α/β在体外和体内联合治疗人肝癌细胞的疗效。本研究以增强抗肿瘤作用为目的，对该抗体进行分子改造，建立了三功能特异性抗体。

For advanced hepatocellular carcinoma has not been established at all treatments, we' ve been doing this research for the purpose of development of therapeutic antibodies as ideal therapeutic agents. We have shown that interferon(IFN)-α/βinduced the up-regulation of fibroblast growth factor receptor-1(FGFR-1) expression in several human liver cancer cells. Based on this result, we have created several anti-FGFR-1 monoclonal antibodies(MoAbs). We revealed that the efficacy of combined treatment with anti-FGFR-1 MoAb and interferon-α/βin human liver cancer cells in vitro and in vivo. The aim of this antibody therapy is more potent anti-cancer effects, we performed molecular alterations of this antibody, and established a tri-functional specific antibody in this study.